Comparative study of anti-inflammatory and ulcerogenic activities of different cyclo-oxygenase inhibitors

被引：10

作者：

Gambero A. ^{[1
]}

Becker T.L. ^{[1
]}

Zago A.S. ^{[1
]}

De Oliveira A.F. ^{[1
]}

Pedrazzoli Jr. J. ^{[1
]}

机构：

[1] Clinical Pharmacology and Gastroenterology Unit, São Francisco University Medical School, 12916-900, Braganca Paulista, SP

来源：

InflammoPharmacology | 2005年 / 13卷 / 5-6期

关键词：

Air pouch; Cyclo-oxygenases; Leukocyte; Non-steroidal anti-inflammatory drugs; Prostaglandin E[!sub]2[!/sub;

D O I：

10.1163/156856005774649377

中图分类号：

学科分类号：

摘要：

The aim of the present work was to study the in vivo anti-inflammatory activity of six NSAIDs, ibuprofen, diclofenac, nimesulide, meloxicam, celecoxib and rofecoxib, using the rat air-pouch model of inflammation to characterize the ability of these drugs to induce gastric damage and PGE2 inhibition. Selective compounds were observed to have no ulcerogenic properties at antiinflammatory doses; however, these drugs were weaker inhibitors of several inflammatory aspects such as cell influx and exudate formation. In contrast, the non-selective and preferential compounds present anti-inflammatory properties at lower doses than presented by selective drugs. At antiinflammatory doses, only meloxicam and ibuprofen produced gastric damage and inhibition of PGE 2 synthesis, suggesting that ulcerogenic properties of NSAIDs cannot be predicted by their selectivity index, since meloxicam demonstrates ulcerogenic properties despite its preferential profile. © VSP 2005.

引用

页码：441 / 454

页数：13

共 37 条

[1]

Adams I., Neuman R.G., Sachs J., Et al., Efficacy and gastric safety of etodolac as determined in cultured human gastric and synovial cells, Gastroenterology, 24, pp. 40-47, (1990)

[2]

Bennett A., Villa G., Nimesulide: An NSAID that preferentially inhibits COX-2, and has various unique pharmacological activities, Expert. Opin. Pharmacother., 1, pp. 277-286, (2000)

[3]

Blain H., Boileau C., Lapicque F., Et al., Limitation of the in vitro whole blood assay for predicting the COX selectivity of NSAIDs in clinical use, Br. J. Clin. Pharmacol., 53, pp. 255-265, (2002)

[4]

Chan C.C., Boyce S., Brideau C., Et al., Rofecoxib [Vioxx, MK-0966

[5]

4-(4′-methylsulfonylphenyl)-3-phenyl-2- (5H)-furanone]: A potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles, J. Pharmacol. Exp. Ther., 290, pp. 551-560, (1999)

[6]

Cullen L., Kelly L., Connor S.O., Et al., Selective cyclooxygenase-2 inhibition by nimesulide in man, J. Pharmacol. Exp. Ther., 287, pp. 578-582, (1998)

[7]

De Leval X., Delarge J., Devel P., Et al., Evaluation of classical NSAIDs and COX-2 selective inhibitors on purified ovine enzymes and human whole blood, Prostaglandins Leukot. Essent. Fatty Acids, 64, pp. 211-216, (2001)

[8]

Dvornik D.M., Tissue selective inhibition of prostaglandin biosynthesis by etodolac, J. Rheumatol., 14, pp. 40-47, (1997)

[9]

Ehrich E.W., Dallob A., De Lepeleire I., Characterization of rofecoxib as a cyclooxigenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model, Clin. Pharmacol. Ther., 65, pp. 336-347, (1999)

[10]

Engelhardt G., Pharmacology of meloxicam, a new non-steroidal anti-inflammatory drug with an improved safety profile through preferential inhibition of COX-2, Br. J. Rheumatol., 35, pp. 4-12, (1996)

← 1 2 3 4 →